Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
Date:5/18/2010

CALGARY, AB, May 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," has been published in the online version of the journal Clinical Cancer Research.

The paper covers final results from a Phase Ia/Ib U.K. clinical trial (REO 006) investigating the intratumoural delivery of REOLYSIN(R) in combination with radiation to treat patients with advanced cancers. A total of 23 patients received a range of two to six intratumoural doses of REOLYSIN at escalating dosages up to a maximum of 1x10(10) TCID(50) with a constant localized radiation dose of either 20 Gy or 36 Gy. The principal investigator for the study is Dr. Kevin Harrington from The Institute of Cancer Research and The Royal Marsden Hospital, London, U.K.

Of the seven evaluable patients in the low-dose (20Gy) radiation group, two patients had a partial response (PR) (esophageal adenocarcinoma and squamous cell carcinoma (SCC) of the skin) and five had stable disease (SD) including patients with malignant melanoma, pancreatic adenocarcinoma, SCC of the larynx and SCC of the skin (2). In the high-dose (36Gy) radiation group, five of seven evaluable patients had PRs (malignant melanoma (2), lung adenocarcinoma, colorectal adenocarcinoma, and ovarian adenocarcinoma) and two had SD (malignant melanoma).

"All 14 patients considered evaluable for treatment response in this study had SD or better for a clinical benefit rate of 100%," said Dr. Brad Thompson, President and CEO of Oncolytics. "We believe that this study clearly demonstrates that the combination of low dose radiation and REOLYSIN is well tolerated and that the very high response rate warrants further investigation."

The primary objective of the trial was to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of REOLYSIN when administered intratumourally to patients receiving radiation treatment. A secondary objective was to examine any evidence of anti-tumour activity. The treatment was well tolerated in all cohorts, with no DLTs, and no MTD was reached.

"This is an early study but the absence of any significant side-effects is extremely reassuring for future trials in patients receiving radiotherapy with the aim of curing their cancer," said Dr. Harrington.

About The Institute of Cancer Research (ICR)

    -   The ICR is Europe's leading cancer research centre
    -   The ICR has been ranked the UK's top academic research centre, based
        on the results of the Higher Education Funding Council's Research
        Assessment Exercise
    -   The ICR works closely with partner The Royal Marsden NHS Foundation
        Trust to ensure patients immediately benefit from new research.
        Together the two organisations form the largest comprehensive cancer
        centre in Europe
    -   The ICR has charitable status and relies on voluntary income,
        spending 95 pence in every pound of total income directly on research
    -   As a college of the University of London, the ICR also provides
        postgraduate higher education of international distinction
    -   Over its 100-year history, the ICR's achievements include identifying
        the potential link between smoking and lung cancer which was
        subsequently confirmed, discovering that DNA damage is the basic
        cause of cancer and isolating more cancer-related genes than any
        other organisation in the world

For more information visit www.icr.ac.uk

The Royal Marsden Hospital

The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer treatment, research and education. Today, together with its academic partner, The Institute of Cancer Research, it is the largest and most comprehensive cancer centre in Europe treating over 40,000 patients every year. It is a centre of excellence, and the only NHS Trust to achieve the highest possible ranking in the Healthcare Commission's Annual Health Check for the fourth year in a row. Since 2004, the hospital's charity, The Royal Marsden Cancer Campaign, has helped raise over (pnds stlg)50 million to build theatres, diagnostic centres, and drug development units. Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital. For more information, visit www.royalmarsden.nhs.uk

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Clinical Cancer Research" with respect to REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
2. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
4. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
5. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Oncolytics Biotech(R) Inc. Announces Unit Offering
8. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
10. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 Acupath Laboratories, ... announces the formation of an Executive Committee that will ... beyond. John Cucci , a 15-year ... from Director of Business Development to Chief Sales ... Mr. Cucci served in senior sales leadership roles at ...
(Date:1/18/2017)... Jan. 18, 2017   Boston Biomedical , an ... to target cancer stemness pathways, will feature data from ... at the 2017 ASCO Gastrointestinal Cancers Symposium, held from ... Napabucasin is an orally-administered investigational agent ... i Cancer stem cells (CSCs) possess the property ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports ... A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long ... an anterior cervical discectomy and fusion on a 42 year old female who ...
(Date:1/18/2017)... NY (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... do not fall low enough after prostate cancer treatment, this indicates there is still remaining ... risk of mortality. , “ The PSA test has always been an indicator of whether ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/15/2016)... ... and Markets has announced the addition of the "Global Military Biometrics ... forecasts the global military biometrics market to grow at a CAGR of ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
(Date:12/8/2016)... PUNE, India , Dec. 8, 2016 Market Research ... and Service Market. The global Mobile Biometric Security and Service Market ... period 2016 to 2022. Market Highlights: ... , , ... fast pace due to the increasing need of authentication and security ...
Breaking Biology News(10 mins):